Form 4: Lineage Cell Therapeutics GC Reports RSU Vesting

Lineage Cell Therapeutics' General Counsel, George A. Samuel III, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Summary

• George A. Samuel III, General Counsel and Secretary of Lineage Cell Therapeutics, Inc., reported changes in beneficial ownership.
• On December 19, 2025, Samuel acquired 1,735 common shares due to the vesting of restricted stock units (RSUs).
• These RSUs were granted on February 11, 2022, and their vesting was contingent on certain performance conditions.
• Concurrently, 65 common shares were disposed of by the issuer at a price of $1.68 per share to satisfy statutory tax withholding requirements related to the RSU vesting.
• No shares were sold by Samuel in connection with this transaction.
• Following these transactions, Samuel beneficially owns 27,490 common shares directly.
• This total does not include unvested RSUs that may be settled in common shares or common shares that may be acquired upon the exercise of certain outstanding stock options.

Sentiment

Score: 5

Explanation: This is a routine, non-discretionary insider transaction report (Form 4) detailing the vesting of restricted stock units and subsequent tax withholding. It does not contain information that would significantly alter the sentiment towards the company, hence a neutral score.

Positives

• The vesting of 1,735 restricted stock units (RSUs) indicates that performance conditions, set when the RSUs were granted on February 11, 2022, were successfully met.
• The transaction is a routine, non-discretionary event, reflecting a planned compensation structure for the General Counsel and Secretary.

Negatives

• No direct negatives are apparent from this routine insider transaction report. The disposition of shares was solely for tax withholding purposes, not a discretionary sale by the reporting person.

Future Outlook

This filing is a report of past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction report common across all publicly traded companies, reflecting a standard component of executive compensation in the biotechnology and cell therapeutics industry. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation, with vesting contingent on performance conditions, is a common practice across industries, including biotechnology, aligning executive incentives with company performance.
• The withholding of shares to cover statutory tax obligations upon RSU vesting is a standard, administrative procedure for equity compensation plans, consistent with practices at comparable companies like Gilead Sciences or Regeneron Pharmaceuticals.

Stakeholder Impact

• Shareholders: This routine transaction has minimal direct impact on shareholders, as it reflects a standard component of executive compensation and does not involve a discretionary sale of shares by the insider.
• Employees: The vesting of performance-based RSUs may signal the achievement of internal company goals, potentially boosting morale.

Key Dates

Keywords

Lineage Cell Therapeutics, LCTX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, George A. Samuel III